Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.
Frédéric CailleuxElisa AgostinettoMatteo LambertiniFrançoise RothéHsin-Ta WuMustafa BalciogluEkaterina KalashnikovaDelphine VincentGiulia VigliettiAndrea GombosAndreas PapagiannisIsabelle VeysAhmad AwadaHimanshu SethiAlexey AleshinDenis LarsimontChristos SotiriouDavid VenetMichail IgnatiadisPublished in: JCO precision oncology (2022)
The presence of ctDNA after neoadjuvant chemotherapy is associated with relapse in early-stage breast cancer, supporting interventional trials for testing the clinical utility of ctDNA monitoring in this setting.